루닛

328130KOSDAQ

49.5 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment20.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 18.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Lunit is a deep learning-based medical AI company specializing in cancer diagnosis and breast cancer screening solutions, leveraging AI-assisted detection and imaging biomarker technologies. Its core products, Lunit INSIGHT and Lunit SCOPE, drive innovation in the medical AI market, with 92% of revenue generated from overseas markets, including the U.S. and Japan.

Number of Employees

272people

Average Salary

93.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.81Industry Average 1.200.0Point

4.0x industry avg (risky)

ROE

-31.58Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

14.75Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲84.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼41.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -32.3% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 0Negative 1Average Sentiment Score 82.1

Positive
의료AI 루닛, CB 상환·유증 다음은 '수익성 증명'
루닛은 해외 사업 확장과 비용 효율화를 통해 상각 전 영업이익 흑자 전환을 목표로 설정, 긍정적인 재무 전망을 제시했습니다.
Negative
루닛, CB 조기상환에 751억 투입…남은 과제는 '흑전 약속'
루닛의 주가 하락으로 인해 CB 조기상환 자금 투입이 증가했으나, 흑전 달성에 대한 불확실성이 존재하여 투자자들의 불안감이 높다.
Positive
루닛, 의료 특화 AI 모델 첫 해커톤 성료…70여 명 참여
루닛의 의료 특화 AI 모델 해커톤 성공으로 혁신적인 서비스 개발 및 임상 검증 단계 진입.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,870Won52-week high 45,92852-week low 8,520

1-month return0.0Point

1m -18.32% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral전환가액의조정2026-09-04
Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-31
Neutral주식매수선택권부여에관한신고2026-08-20
Neutral반기보고서 (2026.06)2026-08-11